CSIMarket
 
Eton Pharmaceuticals Inc   (ETON)
Other Ticker:  
 
 
Price: $3.8500 $-0.61 -13.677%
Day's High: $4.21 Week Perf: -15.57 %
Day's Low: $ 3.85 30 Day Perf: -12.3 %
Volume (M): 196 52 Wk High: $ 5.81
Volume (M$): $ 755 52 Wk Avg: $3.99
Open: $4.00 52 Wk Low: $2.42



 Market Capitalization (Millions $) 90
 Shares Outstanding (Millions) 23
 Employees -
 Revenues (TTM) (Millions $) 31
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 1

Eton Pharmaceuticals Inc
Eton Pharmaceuticals Inc is a specialty pharmaceutical company that focuses on developing and commercializing innovative treatments for various diseases and disorders. The company's main emphasis is on developing products that have a high need in the market, yet are underserved or have limited competition. Eton Pharmaceuticals aims to offer cost-effective solutions that improve patient outcomes and enhance quality of life. They have a strong pipeline of products in development across multiple therapeutic areas, including neurology, hospital, and rare diseases.


   Company Address: 21925 W. Field Parkway, Suite 235 Deer Park 60010 IL
   Company Phone Number: 787-7361   Stock Exchange / Ticker: NASDAQ ETON
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Eton Pharmaceuticals Inc

Eton Pharmaceuticals Inc Struggles as Deficit Widens Amid Decrease in Orders

Eton Pharmaceuticals Inc Faces Challenges as Lower Demand Leads to Fading Revenue and Higher Deficit
DEER PARK, Ill., March 14, 2024 - Eton Pharmaceuticals Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, recently reported financial results for the fourth quarter and year ended December 31, 2023. The company faced significant challenges during this period due to lower demand, leading to fading revenue and a higher deficit.
During the fourth quarter of 2023 earnings season, Eton Pharmaceuticals Inc posted a deficit per stock of -$0.09 per share, a significant decline compared to the preceding financial reporting period where they realized a bottom line of -$0.02 per share. Additionally, the company reported a drop in revenue by -9.72% to $7.67 million compared to the previous year.

Product Service News

Addressing the Unmet Needs of Rare Disease Patients: The Commercial Availability of Nitisinone Capsules for Hereditary Tyrosinemia Type 1

Published Fri, Feb 2 2024 11:50 AM UTC

Rare diseases affect a small percentage of the population, often making it challenging for pharmaceutical companies to invest in developing treatments. However, Eton Pharmaceuticals, an innovative pharmaceutical company, is aiming to address this issue by focusing on developing, acquiring, and commercializing products to meet the unmet needs of patients suffering from rare d...

Eton Pharmaceuticals Inc

Major Pharmaceutical Preparations Company Records Impressive 98.913% Revenue Growth in Q3 2023

Eton Pharmaceuticals Inc (ETON) has recently released its third-quarter earnings report for 2023, showcasing a substantial improvement in its financial performance compared to the same period last year. This bullish development is expected to impact the company positively and potentially attract more investors.
In terms of earnings per share (EPS), ETON reported a net loss of $-0.02 per share for the third quarter of 2023, significantly narrower than the $-0.12 loss reported in the previous year. This showcases the company's efforts in improving its bottom line and efficiency over time.

Eton Pharmaceuticals Inc

Eton Pharmaceuticals Inc Boasts Impressive 58.766% Surge in Revenue, Positively Outperforming Industry Competitors

Eton Pharmaceuticals Inc has recently shown impressive financial results, with a significant turnaround in earnings. In the most recent fiscal period, the company reported earnings per share (EPS) of $0.18, compared to a loss of $0.06 per share in the previous year. Additionally, EPS improved from a loss of $100.00 per share in the prior quarter. This positive trend in earnings is a clear indication of the company's improved financial performance.
Notably, Eton Pharmaceuticals Inc experienced a substantial increase in revenue, with a 58.766% rise to $11.68 million from $7.36 million in the same quarter of the previous year. Furthermore, the sequential revenue doubled by 120.249%, reaching $5.30 million. These figures highlight Eton Pharmaceuticals Inc's ability to withstand the declining momentum faced by its contemporaries in the Major Pharmaceutical Preparations sector. While others in the industry experienced a decline in business, Eton Pharmaceuticals Inc managed to surge ahead.

Eton Pharmaceuticals Inc

ETON Struggles to Achieve Break-Even Amidst an Unprecedented Surge in Revenue

Eton Pharmaceuticals Inc, a pharmaceutical company that specializes in developing innovative solutions for rare diseases, recently announced a strong revenue rise of 143.75% year on year to $5.30 million in the financial three months ending March 31st, 2023.
While this significant jump in revenue is impressive, the company also reported an increased deficit per share at -$100.00. This means that the company's net loss per share has widened since the previous reporting period, where earnings per share were at $0.04 per share. Additionally, revenue tumbled by -37.585% from $8.50 million in the previous period, suggesting a decline in sales.






 

Eton Pharmaceuticals Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Eton Pharmaceuticals Inc does not provide revenue guidance.

Earnings Outlook
Eton Pharmaceuticals Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com